Treatment of relapsing polychondritis in the era of biological agents.
Rheumatol Int
; 30(6): 827-8, 2010 Apr.
Article
en En
| MEDLINE
| ID: mdl-20020132
ABSTRACT
Relapsing polychondritis (RP) is a rare disorder, often requiring high doses of immunosuppressive therapy to control its potentially life-threatening consequences. The advent of biological agents has added to the armamentarium available to treat RP, but the lack of controlled trials, along with the small numbers of patients and disease heterogeneity means that new therapies are prescribed without the benefits of rigorous clinical research. Thus, information on individual cases is of value in expanding our knowledge of the use of biologic agents in rare conditions. We report on the use of rituximab in a patient who subsequently developed catastrophic aortic incompetence, and we review the literature in relation to the use of this drug in RP.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Insuficiencia de la Válvula Aórtica
/
Policondritis Recurrente
/
Inmunosupresores
/
Anticuerpos Monoclonales
Tipo de estudio:
Etiology_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Rheumatol Int
Año:
2010
Tipo del documento:
Article
País de afiliación:
Irlanda